CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that Director of Business Development Glenn Reiser will be presenting its breakthrough non-opiate pain platform at the Life Sciences Summit 2015 held in New York, NY on December 1, 2015.
Pixar Bio’s presentation:
| Date: | Tuesday, December 1, 2015 | ||||
| Time: | 10:00 AM EST | ||||
| Location: | 10th Floor, Park at Time Warner Center, 60 Columbus Circle, New York, NY 10019 | ||||
“The marketplace, whether is physicians, patients, hospital administrators, USFDA, CMS, private insurers, or drug rehab centers, they have all been loud and clear in demanding a novel non-opiate, non-addictive pain platform and we’ve delivered. Based on our recent US FDA meeting we forecast first product approvals in early 2018, with as many as eight USFDA approved labels for a range of pain indications by 2020. We have the potential to remove clinic based addiction from the healthcare system, but also eliminate other opiate related addictions. Our RSB R&D model will quickly bring a range of pain products to market for knee, hip, shoulder, trigeminal neuralgia, dentistry among other pain conditions. My team has developed into an efficient innovation engine, and we’re seeing NeuroRelease related breakthroughs for challenging neurological areas outside of pain becoming common in our labs,” said PixarBio CEO Frank Reynolds.
The 2015 Life Sciences Summit is an investor and business development conference that highlights emerging medical device and biotechnology companies. The objective of the event is to connect biotech innovators with capital and industry partners to move new discoveries into clinical development.
About PixarBio Corporation
Cofounded by Frank Reynolds,
MIT’s Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione,
PixarBio is focused on researching and developing targeted drug and cell
delivery systems to treat pain, epilepsy, Parkinson’s disease, and
spinal cord injury. For more information visit www.pixarbio.com.